Actively Recruiting
Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project
Led by Endeavor Health · Updated on 2025-07-31
20
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this randomized clinical trial is to evaluate if we can use placental pathology in a prior pregnancy which had an adverse outcome, such as early delivery, stillbirth, a baby born smaller than expected, or severe forms of high blood pressure during pregnancy, to guide treatment in the subsequent pregnancy and reduce risk of recurrent adverse pregnancy events. The main questions it aims to answer are: * Whether enoxaparin prevents recurrent adverse pregnancy outcomes among patients with a prior adverse pregnancy outcome that occurred in the setting of maternal vascular malperfusion (MVM). * If enoxaparin reduces the occurrence or severity of MVM among patients with a prior adverse pregnancy outcome that occurred in the setting of MVM.
CONDITIONS
Official Title
Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Prior adverse pregnancy outcome including singleton preterm birth before 37 weeks, small for gestational age infant under 10th percentile, severe preeclampsia, or stillbirth after 20 weeks confirmed by an obstetrician
- Maternal vascular malperfusion confirmed on placental pathology from the prior adverse pregnancy
- Current singleton pregnancy less than 16 weeks and 6 days gestational age
You will not qualify if you...
- Planned anticoagulation treatment during current pregnancy including warfarin, enoxaparin, or heparin
- Known major fetal anomaly
- Contraindication to enoxaparin such as active major bleeding, thrombocytopenia (platelets below 100), hypersensitivity to enoxaparin, heparin, pork products, or benzyl alcohol
- Chronic kidney disease with estimated glomerular filtration rate (eGFR) below 60
- Known chronic liver disease with baseline AST/ALT over 3 times the upper limit of normal
- Presence of mechanical prosthetic heart valves
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NorthShore University HealthSystem
Evanston, Illinois, United States, 60201
Actively Recruiting
Research Team
S
Sunitha Suresh
CONTACT
K
Kate Honeyfield
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here